Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 5 | 3 |
List of Tables | 6 | 1 |
List of Figures | 7 | 1 |
Direct to Consumer (DTC) Advertising in Pharmaceuticals -Introduction | 8 | 3 |
Direct to Consumer (DTC) Advertising in Pharmaceuticals Media Types | 11 | 28 |
Traditional Media Types | 13 | 1 |
Television | 13 | 1 |
Introduction | 13 | 1 |
Advertising Regulations and Violative Campaigns | 14 | 2 |
Expenditure | 16 | 1 |
Television Advertising within the Media Mix | 16 | 1 |
Print | 17 | 1 |
Other | 18 | 1 |
Online and Social Media | 18 | 1 |
Introduction | 18 | 1 |
Impact | 18 | 1 |
FDA Guidance | 19 | 1 |
Advertisement Placement | 20 | 1 |
Twitter | 21 | 1 |
Introduction | 21 | 3 |
AstraZeneca s Live Twitter Chat | 24 | 2 |
Shire s @ADHD Support | 26 | 1 |
Facebook | 27 | 1 |
YouTube | 27 | 1 |
Mobile | 28 | 1 |
The Importance of a Mobile-enabled Website | 28 | 1 |
Applications | 28 | 1 |
Managing Media Types | 29 | 1 |
Increasing and Measuring ROI of Social Media | 29 | 7 |
Choosing the Correct Media Mix | 36 | 1 |
Nature of the Disease | 36 | 1 |
Prevalence of the Disease | 37 | 1 |
Consumer Media Preferences and/or Habits | 37 | 1 |
Target Population | 37 | 1 |
Degree of Market Competition | 37 | 1 |
Future Prospects for a Brand | 37 | 1 |
Future Prospects for the Market | 38 | 1 |
DTC Advertising in the US | 39 | 12 |
Introduction | 39 | 1 |
History of DTC in the US | 39 | 2 |
Impact of DTC in the US | 41 | 1 |
Current DTC US Market | 42 | 2 |
FDA Regulations | 44 | 1 |
2011 Guidance for Industry the FDAs Response to Social Media Use | 44 | 1 |
45-Day Ad Review | 45 | 1 |
Innovative Campaign Examples | 46 | 1 |
Lantus (Insulin Glargine) Sanofi US | 46 | 1 |
Spiriva Boehringer Ingelheim Pharmaceuticals Inc. | 46 | 1 |
Controversial Campaign Examples | 47 | 1 |
Copaxone (Glatiramer Acetate) Teva Pharmaceutical Industries | 47 | 2 |
Victoza (Liraglutide [rDNA Origin] Injection) Novo Nordisk A/S | 49 | 2 |
European Union | 51 | 4 |
Introduction | 51 | 1 |
EU Regulations for DTC Advertising | 51 | 1 |
High Level Pharmaceutical Forum A Move to Push Branded DTC Advertising in Europe | 52 | 1 |
EC Proposal on Restricted Branded Advertising Possible Entry Point for DTC Advertising Penetration in the Continent | 52 | 1 |
Budget Cuts and National Health Services | 53 | 1 |
Awareness Campaigns | 53 | 1 |
Dupuytren s Disease it is in your hands | 53 | 1 |
Lust for Life | 53 | 1 |
Conclusion | 54 | 1 |
Other Markets | 55 | 1 |
New Zealand | 55 | 1 |
Trans-Tasman Initiative | 55 | 1 |
Conclusion | 56 | 1 |
Key Takeaway | 57 | 1 |
Appendix | 58 | 5 |
Market Definitions | 58 | 1 |
Social Media Definitions | 58 | 1 |
Abbreviations | 59 | 1 |
Sources | 59 | 1 |
Research Methodology | 60 | 3 |
Coverage | 60 | 1 |
Secondary Research | 61 | 1 |
Primary Research | 61 | 1 |
Competitive Landscape | 61 | 1 |
Expert Panel Validation | 62 | 1 |
Contact Us | 62 | 1 |
Disclaimer | 62 | 1 |